Immunocore Holdings PLC (NASDAQ:IMCR) Beats Q2 2025 Revenue and EPS Estimates with Strong KIMMTRAK Sales Growthchartmill.comImmunocore (IMCR) beat Q2 2025 estimates with $98M revenue (+30% YoY) and a narrower EPS loss. KIMMTRAK sales surged 32%, while pipeline progress and strong cash position ($882.8M) boosted investor confidence.
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?benzinga.comMorgan Stanley downgrades Amicus Therapeutics, Immunocore, and Immuneering, citing pricing challenges, pipeline updates, and cautious growth outlooks.
3 Fast-Growing Stocks Analysts See Doubling in PriceClinical-stage biotech firms often have massive upside potential, but much of that possible success hinges on successful trials and product launches.
3 Small-Cap Stocks with Significant Growth Potentialinvestorplace.comAs sector rotation continues, it could be time for investors to consider these small-cap growth stocks that institutions love.
IMCR Stock Earnings: Immunocore Hldgs Misses EPS, Misses Revenue for Q1 2024investorplace.comIMCR stock results show that Immunocore Hldgs missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
